Aurisco Pharmaceutical Co Ltd (605116) — Cash Flow Reinvestment Rate
Aurisco Pharmaceutical Co Ltd (605116) has a Cash Flow Reinvestment Rate of 3.81x as of December 2024, reinvesting CN¥1.27 Billion (capex CN¥540.28 Million plus investments CN¥-726.77 Million) from operating cash flow of CN¥332.41 Million. Explore 605116 capital expenditure intensity to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Aurisco Pharmaceutical Co Ltd Cash Flow Reinvestment Rate (2017–2024)
Historical reinvestment intensity for Aurisco Pharmaceutical Co Ltd across 8 annual periods. Also explore balance sheet size of Aurisco Pharmaceutical Co Ltd for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Aurisco Pharmaceutical Co Ltd (2017–2024)
Year-by-year capital reinvestment analysis for Aurisco Pharmaceutical Co Ltd. For live market cap and broader valuation context, see 605116 market cap.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 3.81x | CN¥1.27 Billion | CN¥332.41 Million | CN¥540.28 Million | ▲ +119.1% |
| 2023 | 1.74x | CN¥670.75 Million | CN¥385.61 Million | CN¥305.48 Million | ▼ -38.8% |
| 2022 | 2.84x | CN¥473.01 Million | CN¥166.41 Million | CN¥216.23 Million | ▲ +11.7% |
| 2021 | 2.54x | CN¥512.96 Million | CN¥201.57 Million | CN¥250.61 Million | ▲ +72.8% |
| 2020 | 1.47x | CN¥315.81 Million | CN¥214.48 Million | CN¥158.80 Million | ▲ +71.4% |
| 2019 | 0.86x | CN¥154.57 Million | CN¥179.90 Million | CN¥72.47 Million | ▲ +0.2% |
| 2018 | 0.86x | CN¥94.14 Million | CN¥109.77 Million | CN¥94.14 Million | ▼ -5.1% |
| 2017 | 0.90x | CN¥106.60 Million | CN¥117.91 Million | CN¥106.60 Million | — |